Engineered immune cells take on childhood cancers in first human test

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * First 2 subjects enrolled and treated in both Arm A and Arm B: age ≥ 15 and ≤ 30 years * Subsequent subjects: age ≥ 1 and ≤30years * Histologically diagnosed malignant, non-CNS solid tumor expressing EGFR * Evidence of refractory or recurrent disease * Able to tolerate apheresis or has apheresis product available for use in manufacturing * Life expectancy ≥ 8 weeks * Lansky or Karnofsky score ≥ 50 * Recovered from significant acute toxic effects of all prior chemotherapy, immunotherapy, and radiotherapy * If no apheresis product or T cell product is available,≥ 7 days post last chemotherapy/biologic therapy administration * If no apheresis product or T cell product is available,≥ 3 half lives or 30 days, whichever is shorter, post last dose of anti-tumor antibody therapy (including check point inhibitor) * Prior genetically modified cell therapy is allowed if not detectable at enrollment. * If no apheresis product or T cell product is available,≥ 6 weeks post last dose of myeloablative therapy and allogeneic or autologous stem cell transplant * Subjects who receive autologous stem cell infusion following non-myeloablative therapy are eligible once all other eligibility requirements are met * If no apheresis product or T cell product is available,≥ 7 days post last systemic corticosteroid therapy (physiologic replacement dosing is allowed) * If no apheresis product or T cell product is available, subjects with neuroblastoma must be ≥ 12 weeks from I131 MIBG therapy. * Adequate organ function * Adequate laboratory values * Patients of childbearing potential must agree to use highly effective contraception Exclusion Criteria: * Presence of active malignancy other than primary malignant solid tumor diagnosis * Current relevant CNS pathology * Presence of active GVHD, or receiving immunosuppressive therapy for treatment or prevention of GVHD within 4 weeks prior to enrollment * Presence of active severe infection * Presence of primary immunodeficiency syndrome * Receiving external beam radiation therapy at time of enrollment * Receiving any anti-cancer agents or chemotherapy * Pregnant or breastfeeding * Unwilling to provide consent/assent for participation in the study and 15 year follow up period * Presence of any condition that, in the opinion of the investigator, would prohibit the patient from undergoing treatment under this protocol